DGAP-News: Novamind Inc. / Key word(s): Miscellaneous 
Novamind Inc.: Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial 
2021-02-11 / 14:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 
Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial 
Cedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD Treatment 
TORONTO, ON / ACCESSWIRE / February 11, 2021 / Novamind Inc. (CSE:NM) ("Novamind"), a leading mental health company 
specialized in psychedelic medicine, is pleased to announce that it has made a strategic investment of AUUSD827,486 
(approximately CANUSD810,000, the "Strategic Investment"), in Bionomics Limited ("Bionomics") (ASX:BNO)(OTCQB:BNOEF) 
(Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous 
system disorders. 
In addition, Cedar Clinical Research ("CCR"), a wholly owned subsidiary of Novamind based in Springville, Utah, will be 
evaluated by Bionomics as a clinical research site to conduct Bionomics' Phase IIb trial examining BNC210. BNC210 has 
received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress 
disorder (PTSD). 
With its investment in Bionomics, Novamind joins a group of well-known investors that specialize in psychedelics and 
biotech: Apeiron Investments, Biotech Value Fund, Merck & Co., Mike Novogratz, and Peter Thiel, an early investor in 
ATAI Life Sciences. 
Novamind's Strategic Investment is included in Bionomics' latest round of financing, which was underwritten by Apeiron 
Investments and received commitments for AUUSD16,000,000 (approximately CANUSD15,680,000, the "Bionomics Financing"). 
Novamind will purchase a total of 5,706,800 common shares in the Bionomics Financing, at AUUSD0.145 per share, a 20% 
discount to the 30-day volume weighted average price as of February 5^th, 2021. Proceeds from the Bionomics Financing 
will support the initiation of a Phase IIb trial for BNC210, planned for mid-2021. 
Bionomics intends to evaluate Cedar Clinical Research's deep expertise in facilitating Phase I to Phase IV clinical 
trials for leading pharmaceutical companies, and how it may potentially serve as a research site for Bionomics' Phase 
IIb clinical trial examining BNC210 in PTSD patients. 
Cedar Clinical Research, led by Novamind's Chief Medical Officer, Dr. Reid Robison, is currently contracted for seven 
clinical trials with various sponsors, including leading pharmaceutical companies. Dr. Robison has led over 100 
clinical trials in neuropsychiatry, researching a spectrum of psychiatric conditions, including PTSD. 
"I'm happy to welcome Novamind as a strategic investor in Bionomics," said Dr. Errol De Souza, Executive Chairman of 
Bionomics. "Dr. Robison and the team at Cedar Clinical Research have unique experience related to clinical trials for 
mental health therapeutics." 
Yaron Conforti, CEO and Director of Novamind, added, "We are pleased to participate in Bionomics' financing to support 
the development of its novel drug candidate for the treatment of PTSD. Cedar Clinical Research has unique expertise in 
PTSD research, and we look forward to the opportunity to contribute to the development of BNC210." 
To learn more about Cedar Clinical Research, please visit cedarclinicalresearch.com. 
About Bionomics 
Bionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to 
discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, 
currently in development for initiation of a second Phase II trial for the treatment of PTSD, is a novel, proprietary 
negative allosteric modulator of the alpha-7 (?7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a 
strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada). To learn more, please 
visit bionomics.com.au. 
About Novamind 
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, 
retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments 
through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization 
specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar 
Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental 
wellness and guiding people through their entire healing journey, visit novamind.ca. 
Contact Information 
Novamind 
Yaron Conforti, CEO and Director 
Telephone: +1 (647) 953 9512 
Bill Mitoulas, Investor Relations 
Email: bill@novamind.ca 
Forward-Looking Statements 
This news release contains forward-looking statements. All statements other than statements of historical fact included 
in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that 
such statements will prove to be accurate and actual results and future events could differ materially from those 
anticipated in such statements. Important factors that could cause actual results to differ materially from the 
Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is 
cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this 
news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this 
news release are made as of the date of this news release and the Company will update or revise publicly any of the 
included forward-looking statements as expressly required by applicable laws. 
SOURCE: Novamind Inc. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-02-11 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=----------------------------------------------------------------------------------------------------------------------

1167619 2021-02-11

(END) Dow Jones Newswires

February 11, 2021 08:01 ET (13:01 GMT)